Lupus (SLE): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ACE2 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Metabolic microenvironments in humoral immunity (MicroMeta)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €1,990,728· until Jan 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Early and sensitive detection of renal involvement and treatment responses in lupus patients using non-invasive biomarkers (EARLINESS)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €226,441· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Understanding the Interaction of T cells and Immune Complexes in Systemic Lupus Erythematosus (TICI-SLE)

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €265,648· until Aug 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SInGle cells iN AuToimmUne inflammatoRy disEases (SIGNATURE)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spain· EU contribution €2,630,239· until Dec 2026· 7 countries

4 of 4 running projects, newest first. Listed amounts together: €5.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 1
• Gene Expression Profiling 101
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 38
• Deep Learning 3
• Cohort Studies 111
• Genome-Wide Association Study 55

• Genetic determinants of childhood onset systemic lupus erythematosus.

  Lupus Sci Med, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.